ArticleAnnals of hematology2026
Comparison of time to therapy initiation, therapeutic strategies and survival in patients with MDS IB1, IB2 and AML-MR using data of the duesseldorf registries.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2022, the ICC redefined AML by lowering marrow blast count to 10% herewith integrating former MDS IB2 into AML. To evaluate the clinical implications of this reclassification, we analyzed data of our Duesseldorf registries regarding different aspects in patients with MDS IB1, IB2 or AML-MR and included 928 patients suffering from IB1 (213 patients), IB2 (279 patients) and AML-MR (436 patients). We analyzed time to initiation of treatment as well as treatment strategies and survival times. Time to initiation of therapy was significantly shorter in patients with AML-MR compared to MDS IB2 and IB1 (0.5 vs. 2 vs. 5 months, p < 0.001). Median overall survival was 12 months in patients with AML-MR, 19 months in MDS IB2 and 27 months in MDS IB1 (p < 0.001). Regarding most intensive treatment, median overall survival did not differ significantly in patients undergoing allografting or induction chemotherapy but was significantly longer (p < 0.001) in patients with MDS IB1 or IB2 compared to AML-MR receiving HMA (29 vs. 20 vs. 9 months), low dose chemotherapy (18 vs. 11 vs. 1 months) or BSC only (16 vs. 9 vs. 2 months). The significantly longer time to treatment initiation together with the prolonged median overall survival and survival following treatment with hypomethylating agents (HMAs) or low-dose chemotherapy suggests biologically relevant differences between AML-MR and MDS-IB2 that may not support their classification as a single disease entity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.